Cracking The Code: Understanding Analyst Reviews For Arrowhead Pharma

Analysts' ratings for Arrowhead Pharma ARWR over the last quarter vary from bullish to bearish, as provided by 6 analysts.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $42.17, a high estimate of $50.00, and a low estimate of $29.00. Surpassing the previous average price target of $34.50, the current average has increased by 22.23%.

Interpreting Analyst Ratings: A Closer Look

An in-depth analysis of recent analyst actions unveils how financial experts perceive Arrowhead Pharma. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Arrowhead Pharma. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Arrowhead Pharma compared to the broader market.
• Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Arrowhead Pharma's stock. This comparison reveals trends in analysts' expectations over time.

Capture valuable insights into Arrowhead Pharma's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Arrowhead Pharma analyst ratings.

Discovering Arrowhead Pharma: A Closer Look

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Financial Insights: Arrowhead Pharma

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Decline in Revenue: Over the 3 months period, Arrowhead Pharma faced challenges, resulting in a decline of approximately -49.02% in revenue growth as of 30 September, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Arrowhead Pharma's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -681.36%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Arrowhead Pharma's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -34.48%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -14.05%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: Arrowhead Pharma's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.42.

The Core of Analyst Ratings: What Every Investor Should Know

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.